Current guidelines for type 2 diabetes recommend screening in patients without symptoms of diabetes only if they are older than 40 years of age, and have obesity or overweight. However, a new study urges that screening at-risk patients between 18 and 39 years old would result in better treatment and cost effectiveness. Read more
Physical activity can boost our immune system and response to viruses, lower the stress associated with being in a pandemic, and treat many pre-existing health conditions that are associated with a higher risk of complications or death from COVID-19, according to diabetes exercise expert Dr. Sheri Colberg. Read more
Metformin is the standard first medication treatment of choice for people newly diagnosed with type 2 diabetes. A group of researchers decided to examine whether metformin, which this year celebrates its 63rd anniversary as a type 2 diabetes treatment, continues to earn its spot as a key member of the diabetes medication “All-Star Team.” Read more
A study in Taiwan found the use of a diabetes management app called Health2Sync in combination with Fitbit wearable devices can help users control and better manage the symptoms of type 2 diabetes. Read more
Many older patients with type 2 diabetes deal with polypharmacy — taking multiple medications for their diabetes and other conditions. Polypharmacy can be burdensome in various ways, including multiple side effects of the various medications. Researchers investigated whether the use of polypharmacy put elderly patients at increased risk for hospitalization, falls, and death from all […]
A recent phase 3 clinical trial on the diabetes drug sotagliflozin, an SGLT2 inhibitor, found it had favorable results for people living with severe renal impairment / chronic kidney disease. Read more
People who have prediabetes or type 2 diabetes are usually urged to make lifestyle modifications, including diet, exercise, and weight control as the first form of treatment; metformin is typically the first drug prescribed when lifestyle interventions are insufficient. A recent study examined how the interface of physical activity and metformin affects post-meal glucose in […]
Metformin is the first-line drug treatment for type 2 diabetes, but in some patients, the drug’s effectiveness can decline over time. A clinical trial has found that a combination of two newer diabetes drugs, exenatide and dapagliflozin, is effective in patients whose blood glucose levels did not respond to metformin. Read more
Adequate magnesium in the diet can reduce the risk of both type 2 diabetes and strokes, researchers say, so levels of magnesium should be periodically monitored in patients who are at an increased risk for cardiovascular disease or type 2 diabetes. Read more
Insulin may have reached an evolutionary dead end, a group of scientists say. This means that insulin’s ability to adapt to obesity is limited, which renders most people vulnerable to type 2 diabetes. Read more
Patients with diabetes have a higher risk for developing pneumonia, including viral pneumonia. Since the DPP-4 protein plays a role in infection for some coronaviruses, researchers wanted to study whether using DPP-4 inhibitor diabetes drugs could increase risk for pneumonia. Read more
Uncontrolled or poorly controlled type 2 diabetes is linked to many serious consequences, including death, heart failure, stroke, and myocardial infarction. A recent study compared the use of two antidiabetic medications, SGLT-2 inhibitors (such as Invokana and Jardiance) and GLP-1 receptor agonists (such as Bydureon and Farxiga), to see if one offered better cardiovascular protection. […]
A class of drugs called Nucleoside reverse-transcriptase inhibitors (NRTIs), which has long used to treat HIV and hepatitis B viral infections, appears to prevent the development of type 2 diabetes in a substantial number of patients who take these drugs, according to a new data analysis. Read more
A type of wrinkled “super pea” could potentially help control blood sugar levels and thus reduce the risk of type 2 diabetes, according to researchers from the Imperial College London, the John Innes Centre, Quadram Institute Bioscience and University of Glasgow, UK. The researchers suggest incorporating the peas into foods, whether as whole pea seeds […]
Cardiovascular issues in people with type 2 diabetes are approximately twice as common as in individuals without type 2. The results of a large trial, REWIND, suggest that dulaglutide (also called Trulicity) has cardioprotective properties. Read more
Researchers examining the effects of combining the diabetes drugs canagliflozin, an SGLT2i, plus liraglutide, a GLP-1 RA, found that the combo was not much more effective than for lowering HBA1c than liraglutide alone, but the combo did have some weight loss benefits. Read more
The SGLT-2 inhibitors are a relatively new treatment for type 2 diabetes, and the authors of this study felt their use had not yet been adequately studied in the elderly. They examined the effect of one SGLT-2 inhibitor, dapagliflozin (brand name Farxiga) to assess its effects on blood glucose control and kidney health in senior […]
Daily consumption of both green tea and coffee is linked to a lower risk of dying in people with type 2 diabetes, according to research published in the online journal BMJ Open Diabetes Research & Care. The researchers found that drinking 4 or more cups of green tea, plus 2 or more cups of coffee, […]
Selective Serotonin Reuptake Inhibitors (SSRIs) are a type of antidepressants often used to treat children and teenagers. While one study found an increased risk of type 2 diabetes in Medicaid-insured children prescribed SSRIs (possibly due to weight gain associated with SSRIs), a new study says the risk may not be as great as was thought. […]
A study based in London, U.K., found that adults of South Asian and African Caribbean ethnicity are more likely to be diagnosed with early-onset type 2 diabetes than white adults. Physicians should be aware of the elevated risk and focus on management and prevention of type 2 risk in young adults of these ethnicities, the […]
